| Bioactivity | PKM2/PDK1-IN-1, one of shikonin thioether derivatives, is a dual inhibitor of PKM2/PDK1. PKM2/PDK1-IN-1 inhibits the proliferation of NSCLC cells, and induces apoptosis. PKM2/PDK1-IN-1 induces intercellular ROS production, and regulates the apoptotic proteins, to involves in mitochondrial and death receptor pathway[1]. |
| Target | PKM2, PDK-1 |
| Invitro | PKM2/PDK1-IN-1 (compound E5) (0.5-4 μM; 24 h) 显示出与 Gefitinib (HY-50895) 的协同抗癌作用[1]。PKM2/PDK1-IN-1 (0.5 μM; 24 h) 调节线粒体和死亡受体通路的凋亡蛋白[1]。PKM2/PDK1-IN-1 (0.5 μM, 1 μM; 24 h) 在肺癌细胞中引起线粒体跨膜电位 (ΔΨm) 耗散和细胞内 ROS 积累[1]。PKM2/PDK1-IN-1 (1 μM，2 μM；24 小时) 抑制 PDK1 并增强 H1975 细胞中的下游 PDH 活性[1]。PKM2/PDK1-IN-1 抑制细胞内 NADPH 浓度并增加 H1975 细胞的 ATP 产生[1]。 Cell Viability Assay[1] Cell Line: |
| In Vivo | PKM2/PDK1-IN-1 (compound E5) (2.4 mg/kg，4.8 mg/kg；2天6次，共 11 天) 在体内抑制裸鼠H1975异种移植瘤的生长，毒副作用小[1]。 Animal Model: |
| Name | PKM2/PDK1-IN-1 |
| Formula | C36H43NO7S3 |
| Molar Mass | 697.92 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lin H, et al. PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism. Eur J Med Chem. 2023 Mar 5;249:115166. |